Cleerly is the developer of an AI-powered cardiac imaging platform focused on quantitative coronary CT analysis, and this is a weekly summary of its notable news. The company highlighted new data from the INVICTUS registry showing 94.4% agreement between its AI-based quantitative coronary CT (AI-QCT) technology and intravascular ultrasound (IVUS), an invasive gold-standard for coronary plaque quantification.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cleerly framed this high concordance as a scientific milestone for more accurate, accessible, and less invasive plaque characterization across 17 participating centers. By positioning AI-QCT as a clinically credible alternative to IVUS, Cleerly aims to integrate its platform into routine cardiology workflows and strengthen its evidence base with physicians and health systems.
The company also underscored that robust multi-center registry evidence could differentiate its offering in the competitive cardiac imaging and AI diagnostics market. While the LinkedIn post did not disclose financial metrics or specific commercial contracts tied to INVICTUS, the validation data may support future reimbursement discussions, strategic partnerships, and broader deployment with hospitals and cardiology practices.
In parallel, Cleerly announced plans to showcase its AI cardiac imaging platform at the American College of Cardiology’s ACC.26 conference in New Orleans from March 28 to 30. The company will demonstrate how its technology augments coronary CT angiography by generating 3D coronary artery models and color-coded plaque maps to support more precise assessment of coronary artery disease.
Conference visibility at ACC.26 is intended to deepen engagement with cardiologists, guideline influencers, and provider organizations. If Cleerly can translate interest from live demonstrations into new clinical deployments or long-term software agreements, it would reinforce its recurring revenue potential and support its positioning in preventive cardiology and value-based care.
Overall, the week was marked by strengthening clinical validation of Cleerly’s AI-QCT technology and proactive commercialization efforts through a major cardiology conference presence, both of which may bolster its future growth prospects in cardiac imaging and AI-enabled diagnostics.